0.8711

5.91% -0.0547

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $0.8711, with a volume of 90,881. It is down -5.91% in the last 24 hours and down -12.81% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Previous Close:

$0.9258

Open:

$0.9101

24h Volume:

90,881

Relative Volume:

0.90

Market Cap:

$10.12M

Revenue:

$153.00K

Net Income/Loss:

$-10.93M

P/E Ratio:

-0.6059

EPS:

-1.4378

Net Cash Flow:

$-10.72M

1W Performance:

-11.00%

1M Performance:

-12.81%

6M Performance:

-31.41%

1Y Performance:

-58.91%

1-Day Range:

$0.8707

$0.9425

1-Week Range:

$0.8707

$0.9853

52-Week Range:

$0.8127

$4.1899

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2026-11-12

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	0.8711	10.12M	153.00K	-10.93M	-10.72M	-1.4378
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

Oct 06, 2026

A cancer approach designed to help immune cells fight tumors is the focus of Phio's presentation. - Stock Titan

Oct 06, 2026

Sep 30, 2026

A director buys 10,000 shares of Phio Pharmaceuticals (PHIO) at $1.03 and $1.04 per share. - Stock Titan

Sep 30, 2026

Sep 29, 2026

Phio Pharmaceuticals CEO Robert J. Bitterman Awarded 400,000 Restricted Stock Units - Kalkine Media

Sep 29, 2026

Phio Pharmaceuticals Director Ronald Todd Plott Granted 17,000 Restricted Stock Units - Kalkine Media

Sep 29, 2026

Phio Pharmaceuticals CFO Lisa Cabott Carson Granted 108,000 Restricted Stock Units - Kalkine Media

Sep 29, 2026

A director’s grant at Phio Pharmaceuticals (PHIO) covers 17,000 shares that vest in a year. - Stock Titan

Sep 29, 2026

A CEO's stock award will vest after a year at Phio Pharmaceuticals (PHIO). - Stock Titan

Sep 29, 2026

After a stock award, Phio Pharmaceuticals (PHIO) CFO Lisa Cabott Carson reports holdings of 189,112 shares. - Stock Titan

Sep 29, 2026

Phio Pharmaceuticals Stockholders Endorse 2026 Annual Meeting Proposals Including Director Elections and Incentive Plan Expansion - Kalkine Media

Sep 29, 2026

Sep 25, 2026

Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus

Sep 25, 2026

At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan

Sep 25, 2026

Sep 23, 2026

Phio Pharmaceuticals (PHIO) Chairman, President & CEO Robert Bit - GuruFocus

Sep 23, 2026

A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan

Sep 23, 2026

Sep 18, 2026

Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine

Sep 18, 2026

Sep 17, 2026

Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - kalkinemedia.com

Sep 17, 2026

Sep 16, 2026

Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan

Sep 16, 2026

Sep 15, 2026

Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan

Sep 15, 2026

Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan

Sep 15, 2026

Sep 14, 2026

Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Canada

Sep 14, 2026

Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com UK

Sep 14, 2026

Sep 11, 2026

Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang

Sep 11, 2026

A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan

Sep 11, 2026

Aug 30, 2026